These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29627038)

  • 1. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    Kadrnozkova L; Vaneckova M; Sobisek L; Benova B; Kucerova K; Motyl J; Andelova M; Novotna K; Lizrova Preiningerova J; Krasensky J; Havrdova E; Horakova D; Uher T
    J Neurol Sci; 2018 May; 388():87-93. PubMed ID: 29627038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Uher T; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Ramasamy D; Zivadinov R; Havrdova E; Kalincik T; Horakova D
    Mult Scler; 2017 Jan; 23(1):51-61. PubMed ID: 27053635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R
    J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
    Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis.
    Giorgio A; Stromillo ML; Bartolozzi ML; Rossi F; Battaglini M; De Leucio A; Guidi L; Maritato P; Portaccio E; Sormani MP; Amato MP; De Stefano N
    Mult Scler; 2014 Feb; 20(2):214-9. PubMed ID: 23877971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalamic damage and long-term progression of disability in multiple sclerosis.
    Rocca MA; Mesaros S; Pagani E; Sormani MP; Comi G; Filippi M
    Radiology; 2010 Nov; 257(2):463-9. PubMed ID: 20724544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.
    Lukas C; Minneboo A; de Groot V; Moraal B; Knol DL; Polman CH; Barkhof F; Vrenken H
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1351-6. PubMed ID: 20826873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight-year follow-up study of brain atrophy in patients with MS.
    Fisher E; Rudick RA; Simon JH; Cutter G; Baier M; Lee JC; Miller D; Weinstock-Guttman B; Mass MK; Dougherty DS; Simonian NA
    Neurology; 2002 Nov; 59(9):1412-20. PubMed ID: 12427893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
    Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
    Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.